Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy: a review of clinical measurement and a report of localized 31P measurements of response to treatment

Mark Verrill, Martin Leach, J Glaholm, Timothy Andrew Davies Smith, D Collins, G Payne, J Sharp, S Ronen, Ralph McReady, T Powles, I E Smith

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2-4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri-phosphate (TNTP) (p = 0.02) over 3 (+/-1) weeks were significantly associated with response, as were the levels of PME (p<0.001), PDE (p = 0.01), TP (p = 0.001) and TNTP (p = 0.007) at week 3 (+/-1). PME at week 3 (+/-1) was also significantly associated with the best volume response to treatment (p = 0.03). A reproducibility analysis of results from the observation of normal breast metabolism in four volunteers showed a mean coefficient of variation of 25%, after correcting for changes resulting from the menstrual cycle. Reproducibility studies in four patients with breast cancer showed a mean coefficient of variation of 33%, with the reproducibility being better in patients measured on different days (difference in TP was -6%) compared with those measured on the same day (difference in TP was -29%).
Original languageEnglish
Pages (from-to)314-340
Number of pages27
JournalNMR in Biomedicine
Volume11
Issue number7
Publication statusPublished - 1998

Fingerprint

Magnetic resonance spectroscopy
Phosphorylcholine
Magnetic Resonance Spectroscopy
Phosphates
Breast Neoplasms
Tumors
Nucleosides
Therapeutics
Cellular Spheroids
Chemotherapy
Radiotherapy
Menstrual Cycle
Metabolites
Metabolism
Reproducibility of Results
Disease Progression
Volunteers
Neoplasms
Animals
Breast

Cite this

Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy : a review of clinical measurement and a report of localized 31P measurements of response to treatment. / Verrill, Mark; Leach, Martin ; Glaholm, J; Smith, Timothy Andrew Davies; Collins, D; Payne, G; Sharp, J; Ronen, S; McReady, Ralph; Powles, T; Smith, I E.

In: NMR in Biomedicine, Vol. 11, No. 7, 1998, p. 314-340.

Research output: Contribution to journalArticle

Verrill, M, Leach, M, Glaholm, J, Smith, TAD, Collins, D, Payne, G, Sharp, J, Ronen, S, McReady, R, Powles, T & Smith, IE 1998, 'Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy: a review of clinical measurement and a report of localized 31P measurements of response to treatment', NMR in Biomedicine, vol. 11, no. 7, pp. 314-340.
Verrill, Mark ; Leach, Martin ; Glaholm, J ; Smith, Timothy Andrew Davies ; Collins, D ; Payne, G ; Sharp, J ; Ronen, S ; McReady, Ralph ; Powles, T ; Smith, I E. / Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy : a review of clinical measurement and a report of localized 31P measurements of response to treatment. In: NMR in Biomedicine. 1998 ; Vol. 11, No. 7. pp. 314-340.
@article{479d3150065f4bd79c10122b6d3980ae,
title = "Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy: a review of clinical measurement and a report of localized 31P measurements of response to treatment",
abstract = "A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2-4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri-phosphate (TNTP) (p = 0.02) over 3 (+/-1) weeks were significantly associated with response, as were the levels of PME (p<0.001), PDE (p = 0.01), TP (p = 0.001) and TNTP (p = 0.007) at week 3 (+/-1). PME at week 3 (+/-1) was also significantly associated with the best volume response to treatment (p = 0.03). A reproducibility analysis of results from the observation of normal breast metabolism in four volunteers showed a mean coefficient of variation of 25{\%}, after correcting for changes resulting from the menstrual cycle. Reproducibility studies in four patients with breast cancer showed a mean coefficient of variation of 33{\%}, with the reproducibility being better in patients measured on different days (difference in TP was -6{\%}) compared with those measured on the same day (difference in TP was -29{\%}).",
author = "Mark Verrill and Martin Leach and J Glaholm and Smith, {Timothy Andrew Davies} and D Collins and G Payne and J Sharp and S Ronen and Ralph McReady and T Powles and Smith, {I E}",
year = "1998",
language = "English",
volume = "11",
pages = "314--340",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Measurements of Human Breast Cancer using Magnetic Resonance Spectroscopy

T2 - a review of clinical measurement and a report of localized 31P measurements of response to treatment

AU - Verrill, Mark

AU - Leach, Martin

AU - Glaholm, J

AU - Smith, Timothy Andrew Davies

AU - Collins, D

AU - Payne, G

AU - Sharp, J

AU - Ronen, S

AU - McReady, Ralph

AU - Powles, T

AU - Smith, I E

PY - 1998

Y1 - 1998

N2 - A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2-4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri-phosphate (TNTP) (p = 0.02) over 3 (+/-1) weeks were significantly associated with response, as were the levels of PME (p<0.001), PDE (p = 0.01), TP (p = 0.001) and TNTP (p = 0.007) at week 3 (+/-1). PME at week 3 (+/-1) was also significantly associated with the best volume response to treatment (p = 0.03). A reproducibility analysis of results from the observation of normal breast metabolism in four volunteers showed a mean coefficient of variation of 25%, after correcting for changes resulting from the menstrual cycle. Reproducibility studies in four patients with breast cancer showed a mean coefficient of variation of 33%, with the reproducibility being better in patients measured on different days (difference in TP was -6%) compared with those measured on the same day (difference in TP was -29%).

AB - A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2-4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri-phosphate (TNTP) (p = 0.02) over 3 (+/-1) weeks were significantly associated with response, as were the levels of PME (p<0.001), PDE (p = 0.01), TP (p = 0.001) and TNTP (p = 0.007) at week 3 (+/-1). PME at week 3 (+/-1) was also significantly associated with the best volume response to treatment (p = 0.03). A reproducibility analysis of results from the observation of normal breast metabolism in four volunteers showed a mean coefficient of variation of 25%, after correcting for changes resulting from the menstrual cycle. Reproducibility studies in four patients with breast cancer showed a mean coefficient of variation of 33%, with the reproducibility being better in patients measured on different days (difference in TP was -6%) compared with those measured on the same day (difference in TP was -29%).

M3 - Article

C2 - 9859939

VL - 11

SP - 314

EP - 340

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 7

ER -